Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 4, 2014, Pages 284-291

  Shumaker, Robert ^a   Aluri, Jagadeesh ^a   Fan, Jean ^a   Martinez, Gresel ^a   Ren, Min ^a   Chen, Kun ^a  

^a EISAI INC   (United States)

Author keywords

Food effect; Formulation effect; Healthy subjects; Lenvatinib (E7080); Pharmacokinetics; Safety

Indexed keywords

LENVATINIB; PLACEBO;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIET RESTRICTION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; FLATULENCE; FOOD DRUG INTERACTION; GINGIVA PAIN; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NORMAL HUMAN; OPEN STUDY; OROPHARYNX PAIN; OTALGIA; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; SPRAIN; TABLET FORMULATION; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH DISEASE; VOLUNTEER;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; FOOD-DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINOLINES;

EID: 84897103584     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201937     Document Type: Article

References (21)

1. Dvorak HF, Weaver VM, Tlsty TD, Bergers G. Tumor microenvironment and progression. J Surg Oncol. 2011; 103: 468-474. CrossRef PubMed
2. Verheul HM, Voest EE, Schlingemann RO. Are tumours angiogenesis- dependent? J Pathol. 2004; 202: 5-13. CrossRef PubMed (Pubitemid 38072840)
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669-676. CrossRef PubMed (Pubitemid 36749215)
4. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008; 358: 2039-2049. CrossRef PubMed (Pubitemid 351656458)
5. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010; 60: 222-243. CrossRef PubMed
6. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009; 6: 569-579. CrossRef PubMed
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342. CrossRef PubMed (Pubitemid 38702844)
8. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550. CrossRef PubMed (Pubitemid 44917502)
9. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134. Cross-Ref PubMed (Pubitemid 46089673)
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124. CrossRef PubMed (Pubitemid 46089672)
11. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378: 1931-1939. CrossRef PubMed
12. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8: 592-603. CrossRef PubMed
13. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15: 232-239. CrossRef PubMed
14. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008; 14: 5459-5465. CrossRef PubMed
15. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008; 122: 664-671. CrossRef PubMed (Pubitemid 350308963)
16. Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, Koizumi F, Nishio K, Koyama N, Tamura T. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res. 2011; 17: 2528-2537. CrossRef PubMed
17. Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, Schellens JH, Evans TR. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012; 106: 1598-1604. CrossRef PubMed
18. Sherman SI, Jarzab B, Cabanillas ME, Licitra LF, Pacini F, Martins R, Robinson B, Ball D, McCaffrey J, Shah MH, Bodenner D, Allison R, Newbold K, Elisei R, O'Brien JP, Schlumberger M. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol. 2011; 29 (Suppl): abstr. 5503.
19. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). FDA Guidance: Guidance for Industry. Food-Effect Bioavailability and Fed Bioequivalence Studies. Division of Drug Information, Rockville, MD. December 2002. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126833.pdf. Accessed December 14, 2012.
20. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, Inc.; 1975.
21. Jusko WJ. Guidelines for the collection and analysis of pharmacokinetic data. In: Evans WE, Schentag JJ, Jusko WJ (eds). Applied pharmacokinetics: Principles of therapeutic drug monitoring. Spokane: Applied Therapeutics, Inc.; 1992. p. 1-43.